Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26139092 | 0.80 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL31493487 | 0.78 | ATM (0.39) | ATMKDM4EALDH1A1ALOX15MTNR1A | |
| SCHEMBL31493477 | 0.76 | ATM (0.38) | ATMKDM4EALDH1A1ALOX15DPP4 | |
| SCHEMBL7894278 | 0.75 | ATM (0.50) | ATMKDM4EALDH1A1DPP4DPP8 | |
| SCHEMBL10217397 | 0.75 | ATM (0.50) | ATMKDM4EALDH1A1DPP4DPP8 | |
| SCHEMBL21161443 | 0.75 | ATM (0.50) | ATMKDM4EALDH1A1DPP4DPP8 | |
| SCHEMBL12303982 | 0.74 | DPP4 (0.47) | ATMKDM4EALDH1A1DPP4DPP8 | |
| SCHEMBL10216770 | 0.74 | DPP4 (0.47) | ATMKDM4EALDH1A1DPP4DPP8 | |
| SCHEMBL461983 | 0.74 | DPP4 (0.47) | ATMKDM4EALDH1A1DPP4DPP8 | |
| SCHEMBL31493463 | 0.74 | ALDH1A1 (0.41) | ATMKDM4EALDH1A1ALOX15MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | ATM 143/4885KDM4E 331/4885ALDH1A1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.